← Back to Screener
Regeneron Pharmaceuticals Inc (REGN)
Price$749.41
Favorite Metrics
Price vs S&P 500 (26W)24.18%
Price vs S&P 500 (4W)-7.08%
Market Capitalization$78.82B
P/E Ratio (Annual)17.50x
Indicated Dividend Yield (Annual)0.50%
All Metrics
P/CF (Annual)15.83x
Book Value / Share (Quarterly)$295.71
P/TBV (Annual)2.70x
Indicated Dividend (Annual)$3.52
Revenue Growth (3Y)5.62%
Cash Flow / Share (Quarterly)$35.62
Payout Ratio (TTM)8.22%
Price vs S&P 500 (YTD)-6.90%
Gross Margin (TTM)86.56%
Net Profit Margin (TTM)31.41%
EPS (TTM)$41.55
10-Day Avg Trading Volume0.60M
EPS Excl Extra (TTM)$41.55
Revenue Growth (5Y)11.04%
EPS (Annual)$41.48
Dividend / Share (Annual)$3.44
ROI (Annual)13.26%
Gross Margin (Annual)86.56%
Net Profit Margin (5Y Avg)35.70%
Cash / Share (Quarterly)$81.41
P/E Basic Excl Extra (TTM)17.50x
Revenue Growth QoQ (YoY)2.51%
EPS Growth (5Y)6.33%
P/E Normalized (Annual)17.50x
ROA (Last FY)11.11%
Revenue Growth TTM (YoY)0.99%
EBITD / Share (TTM)$38.24
ROE (5Y Avg)21.37%
Operating Margin (TTM)24.95%
Cash Flow / Share (Annual)$35.62
P/B Ratio2.52x
P/B Ratio (Quarterly)2.60x
Net Income / Employee (Annual)$0
EV / Revenue (TTM)4.37x
Net Interest Coverage (TTM)49.98x
ROA (TTM)11.51%
EPS Growth QoQ (YoY)-2.92%
EV / EBITDA (TTM)15.08x
EPS Incl Extra (Annual)$41.48
Current Ratio (Annual)4.13x
Quick Ratio (Quarterly)3.45x
3-Month Avg Trading Volume0.75M
52-Week Price Return36.65%
EV / Free Cash Flow (Annual)16.64x
P/E Incl Extra (TTM)17.50x
Revenue / Employee (TTM)$1
Tangible BV / Share (Quarterly)$283.82
P/S Ratio (Annual)5.50x
Asset Turnover (Annual)0.35x
52-Week High$821.11
Operating Margin (5Y Avg)35.70%
EPS Excl Extra (Annual)$41.48
CapEx CAGR (5Y)14.58%
Tangible BV CAGR (5Y)28.76%
26-Week Price Return32.93%
Quick Ratio (Annual)3.45x
13-Week Price Return-0.47%
Total Debt / Equity (Annual)0.09x
Current Ratio (Quarterly)4.13x
Enterprise Value$62,663.63
Revenue / Share Growth (5Y)12.34%
Asset Turnover (TTM)0.37x
Book Value / Share Growth (5Y)23.46%
Revenue / Employee (Annual)$1
Inventory Turnover (Annual)0.69x
Pretax Margin (Annual)36.47%
Cash / Share (Annual)$81.41
3-Month Return Std Dev26.28%
Gross Margin (5Y Avg)87.22%
Net Income / Employee (TTM)$0
EBITDA CAGR (5Y)1.24%
EBITDA Interim CAGR (5Y)-3.64%
ROE (Last FY)14.41%
Net Interest Coverage (Annual)19.07x
EPS Basic Excl Extra (Annual)$41.48
P/FCF (TTM)20.93x
Receivables Turnover (TTM)2.40x
EV / Free Cash Flow (TTM)16.64x
Total Debt / Equity (Quarterly)0.09x
EPS Incl Extra (TTM)$41.55
Receivables Turnover (Annual)2.40x
ROI (TTM)13.61%
P/S Ratio (TTM)5.50x
Pretax Margin (5Y Avg)40.02%
Revenue / Share (Annual)$132.07
Tangible BV / Share (Annual)$283.82
Forward P/E16.54x
Free OCF CAGR (5Y)13.45%
Price vs S&P 500 (52W)1.55%
P/E Ratio (TTM)17.50x
EPS Growth TTM (YoY)8.48%
Year-to-Date Return-2.76%
5-Day Price Return0.55%
EPS Normalized (Annual)$41.48
ROA (5Y Avg)16.27%
Net Profit Margin (Annual)31.41%
Month-to-Date Return-2.86%
Cash Flow / Share (TTM)$38.82
EBITD / Share (Annual)$38.26
EPS Growth (3Y)2.76%
Operating Margin (Annual)24.95%
LT Debt / Equity (Annual)0.06x
P/CF (TTM)15.83x
ROI (5Y Avg)19.10%
P/E Excl Extra (TTM)17.50x
LT Debt / Equity (Quarterly)0.06x
EPS Basic Excl Extra (TTM)$41.55
P/TBV (Quarterly)2.70x
Payout Ratio (Annual)8.22%
P/B Ratio (Annual)2.60x
Dividend / Share (TTM)$3.44
Inventory Turnover (TTM)0.69x
Pretax Margin (TTM)36.47%
Book Value / Share (Annual)$295.71
Price vs S&P 500 (13W)-3.34%
Net Margin Growth (5Y)-5.35%
Dividend Yield (TTM)0.47%
Beta0.35x
P/FCF (Annual)20.93x
Revenue / Share (TTM)$133.17
ROE (TTM)14.83%
52-Week Low$476.49
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
3.97
4.06
4.06
4.08
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
REGNRegeneron Pharmaceuticals Inc | 5.50x | 0.99% | 86.56% | 6.33% | $749.41 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Regeneron Pharmaceuticals discovers and commercializes biopharmaceutical products across ophthalmology, immunology, cardiovascular disease, oncology, and rheumatology, with marketed drugs including Eylea HD, Dupixent, Praluent, Libtayo, and Kevzara. The company develops monoclonal and bispecific antibodies independently and through collaborations, including a partnership with Sanofi. Regeneron is advancing next-generation therapies through early-stage partnerships in RNAi and CRISPR-based gene editing.